52414-97-8

Basic information

• Product Name: 3-BROMO-2-NITROTOLUENE
• Synonyms: 3-BROMO-2-NITROTOLUENE 98%;3-bromo-2-nitrobenzene;3-Bromo-2-nitrotoluene,98%;1-BroMo-3-Methyl-2-nitrobenzene;6-Bromo-2-methyl-1-nitrobenzene;3-BROMO-2-NITROTOLUENE;2-Nitro-3-Bromo Toluene
• CAS NO: 52414-97-8
• Molecular Formula: C₇H₆BrNO₂
• Molecular Weight: 216.03
• Product Categories: Aromatic Hydrocarbons (substituted) & Derivatives;Nitro Compounds;Nitrogen Compounds;Organic Building Blocks
• Mol File: 52414-97-8.mol

Chemical Properties

• Melting Point: 25-29 °C(lit.)
• Boiling Point: 267℃
• Flash Point: >230 °F
• Appearance: yellow crystalline low melting mass
• Density: 1.612 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0689mmHg at 25°C
• Refractive Index: 1.6120 (estimate)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-BROMO-2-NITROTOLUENE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-2-NITROTOLUENE(52414-97-8)
• EPA Substance Registry System: 3-BROMO-2-NITROTOLUENE(52414-97-8)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 36/37/39-26-22
• WGK Germany: 3
• Hazardous Substances Data: 52414-97-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H6BrNO2/c1-5-3-2-4-6(8)7(5)9(10)11/h2-4H,1H3

Upstream product

• 88-72-2 1-methyl-2-nitrobenzene 
• 1600-27-7 mercury(II) diacetate 
• 601-87-6 3-methyl-2-nitroaniline 
• 70343-09-8 2,3-dinitro-4-methylaniline 
• 591-17-3 meta-bromotoluene 
• 108-44-1 1-amino-3-methylbenzene 
• 540-80-7 tert.-butylnitrite 
• 5437-38-7 3-methyl-2-nitrobenzoic acid 
• 50424-93-6 3-methyl-2-nitrobenzoyl chloride 
• 60310-07-8 3-Methyl-2-nitrobenzenecarboxamide 

Downstream Products

• 53848-17-2 2-bromo-6-methylaniline 
• 116529-61-4 3-bromo-2-nitrobenzoic acid 
• 95-46-5 2-methylphenyl bromide 
• 60004-40-2 3,2'-Dimethyl-2-nitro-biphenyl 
• 852317-11-4 (S)-N-[3-methyl-2-nitrophenyl]-S-methyl-S-phenylsulfoximine 
• 51417-51-7 7-bromo-1H-indole 
• 78787-83-4 1,4,8-trimethyl-carbazole 
• 1730-37-6 1-methylfluorene 
• 116436-11-4 N-(2-bromo-6-methylphenyl)acetamide 
• 861791-77-7 2-acetylamino-3-bromo-benzoic acid 
• 857544-42-4 [3-(3-carboxy-2-nitro-phenylsulfanyl)-4-methoxy-phenyl]-acetic acid 
• 84186-29-8 3-piperidino-2-nitrotoluene 
• 183492-82-2 (3-methyl-2-nitro-phenyl)-propyl-amine 
• 63471-25-0 1-Bromo-3-bromomethyl-2-nitro-benzene 

Relevant articles and documents

Decarboxylative Halogenation and Cyanation of Electron-Deficient Aryl Carboxylic Acids via Cu Mediator as Well as Electron-Rich Ones through Pd Catalyst under Aerobic Conditions

Simple strategies for decarboxylative functionalizations of electron-deficient benzoic acids via using Cu(I) as promoter and electron-rich ones by employing Pd(II) as catalyst under aerobic conditions have been established, which lead to smooth synthesis of aryl halides (-I, Br, and Cl) through the decarboxylative functionalization of benzoic acids with readily available halogen sources CuX (X = I, Br, Cl), and easy preparation of benzonitriles from decarboxylative cyanation of aryl carboxylic acids with nontoxic and low-cost K4Fe(CN)6 under an oxygen atmosphere for the first time.

GABANERGIC MODULATORS

This invention relates to the use of compounds of benzoindazole derivatives salts and solvates thereof for the preparation of a medicament for modulating alpha2 subtype GABA A receptors. The invention further relates to novel heterocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the use of compounds of formula (I) salts and solvates thereof for the preparation of a medicament for the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain.

Indazole derivatives as CRF antagonists

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in

1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives

Derivatives of 1,3-dihydro-3-(2-hydroxyethyl) -2H-isoindol-1-one are disclosed. The derivatives are useful for treating ulcers in a mammal and for preventing or decreasing the secretion or availability of excessive amounts of gastric or hydrochloric acid in a mammal suffering from hyperchlorhydria and/or associated conditions.